Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact

Kyle LaHucik

Senior Reporter

Sanofi has inked another collaboration with its CRISPR partner Scribe Therapeutics as the duo seeks to create a newer, safer approach to tackling sickle cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Sanofi, Doud­na-found­ed Scribe Ther­a­peu­tics to tar­get sick­le cell dis­ease in new pact

Senior Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact